David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.

David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.